The vaccine will target triple-negative breast cancer. If approved by the FDA, the vaccine will enter its second stage of the trial this year.

During the pandemic, spending on diagnostics and vaccine research skyrocketed, and one of the main beneficiaries was Thermo Fisher, as its catalog of products and services aligned perfectly with ...

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) was downgraded by equities researchers at StockNews.com from a “buy” ...

Thermo Fisher was the pandemic powerhouse, with its products well-aligned to meet the skyrocketing demand for diagnostics and vaccine research. The stock price witnessed a surge during COVID-19.

Shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the twenty-two brokerages that are currently covering the stock, ...